ArticleRevista da Associacao Medica Brasileira (1992)2025
Early detection and treatment of cardiac dysfunction in cancer patients improve overall survival.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies.Journal of thrombosis and thrombolysis · 2026Article
- Real-Time Heartbeat Classification on Distributed Edge Devices: A Performance and Resource Utilization Study.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to analyze the impact of the early detection and treatment of cardiac dysfunction on overall survival in cancer patients.
methodsA retrospective analysis was conducted on clinical data from 60 cancer patients with concurrent cardiac dysfunction, admitted between January 2020 and November 2022. Patients were divided into an early treatment group (n=35), where treatment began within 24 h of diagnosis, and a late treatment group (n=25), where treatment started after 24 h. The clinical efficacy, early diastolic filling velocity, fractional shortening, left ventricular ejection fraction, and Quality of Life Questionnaire-Core 30 scores were compared before and after treatment. Adverse reactions, cardiovascular events, and 1-year survival rates were also evaluated.
resultsThe early treatment group showed higher total effective and survival rates compared to the late group (p<0.05). The post-treatment levels of early diastolic filling velocity, fractional shortening, left ventricular ejection fraction, and Quality of Life Questionnaire-Core 30 scores were statistically significantly higher in the early group (p<0.05), with no notable differences in adverse reactions (p>0.05). Kaplan-Meier analysis revealed a statistically significantly higher 1-year survival probability in the early treatment group (log-rank p=0.02).
conclusionEarly detection and treatment of cardiac dysfunction in cancer patients can improve treatment efficacy and survival rate, better improve cardiac function and quality of life, and reduce the occurrence of adverse cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.